Literature DB >> 18158588

Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells.

Lana Osman1, Mohamed Amrani, Charles Ilsley, Magdi H Yacoub, Ryszard T Smolenski.   

Abstract

HMG-CoA reductase inhibitors (statins) exert pleiotropic effects in the cardiovascular system beyond its cholesterol-lowering action. We aimed to investigate how atorvastatin affects extracellular nucleotide degradation in human endothelial cells, as increased activity of this pathway would facilitate conversion of pro-inflammatory nucleotides into anti-inflammatory adenosine. Primary cultures of human endothelial cells were treated with 1 microM, 10 microM and 100 microM atorvastatin for 24 h. Enzyme assays were performed as well as intact cell studies, to evaluate capacity of cells to degrade ATP to adenosine. Atorvastatin significantly increased ATP breakdown and adenosine formation in the medium of intact cells in a dose-dependent manner. The activities of ATPase, ADPase and ecto-5'-nucleotidase (eN) in cell homogenates following Atorvastatin treatment were also increased while no change was observed in the lactate dehydrogenase activity. We suggest a new mechanism of protective effect of atorvastatin by activation of endothelial enzymes involved in extracellular nucleotide degradation in human endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158588     DOI: 10.1007/s11010-007-9630-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  43 in total

1.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

Review 2.  Ecto-enzyme and signaling functions of lymphocyte CD73.

Authors:  R Resta; Y Yamashita; L F Thompson
Journal:  Immunol Rev       Date:  1998-02       Impact factor: 12.988

3.  3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).

Authors:  U Laufs; D Marra; K Node; J K Liao
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

4.  Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes.

Authors:  D Lukashev; C Caldwell; A Ohta; P Chen; M Sitkovsky
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

Review 5.  Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

Authors:  H S Yee; N T Fong
Journal:  Ann Pharmacother       Date:  1998-10       Impact factor: 3.154

6.  The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.

Authors:  Shigeru Morikawa; Wakako Takabe; Chikage Mataki; Toru Kanke; Takahiro Itoh; Youichiro Wada; Akashi Izumi; Yasushi Saito; Takao Hamakubo; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2002       Impact factor: 4.928

Review 7.  Protective effects of adenosine in myocardial ischemia.

Authors:  S W Ely; R M Berne
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

8.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

9.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.

Authors:  O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  1 in total

1.  Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway.

Authors:  Jun Yang; Congxin Huang; Jian Yang; Hong Jiang; Jiawang Ding
Journal:  Mol Cell Biochem       Date:  2010-08-17       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.